Clinical Trial Update: Bioequivalence Study of Generic Fluorouracil 0.5% Cream and 0.5% Carac® and Placebo [Phase 3]

View source ↗

Summary

Phase 3 bioequivalence study comparing generic fluorouracil 0.5% cream with Carac 0.5% and placebo in actinic keratosis has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Actinic Keratosis

Drugs mentioned

• Carac 0.5% Cream (fluorouracil)
• Fluorouracil 0.5% Cream (generic) (fluorouracil)

Snippet

Sponsor: Spear Pharmaceuticals | Conditions: Actinic Keratoses | Phase 3 | Status: COMPLETED